Author

Junlan Guo

Observed name: Guo, Junlan

Institution: Anyang Tumor Hospital

Observed institutions: Henan University of Science and Technology, Sir Run Run Shaw Hospital, Anyang Tumor Hospital, Zhejiang University

ORCID: 0009-0002-5233-3563

Observed ORCID: 0009-0002-5233-3563

OpenAlex ID: A5103576804

The role of estrogen receptor alpha in mediating chemoresistance in breast cancer cells

2012 · Zhinong Jiang, Junlan Guo, et al. · Journal of Experimental & Clinical Cancer Research · 42

Fusobacterium nucleatum promotes PD-L1 expression in cancer cells to evade CD8+ T cell killing in breast cancer

2024 · Junlan Guo, Pengzhi Zhu, et al. · Human Immunology · 21

COX ‐2 Mediates Immune Evasion and Decreases Chemosensitivity in Breast Cancer Through Activation of the JAK2 / STAT3 Signalling Pathway

2025 · Guohua Liu, Peng Liu, et al. · Immunology · 2

Izalontamab brengitecan for HR+/HER2– breast cancer in China (PANKU-Breast01): a randomised, phase 3 trial

2026 · Bo Lan, Yehui Shi, et al. · The Lancet

A multi-centre, phase 1a/1b dose escalation and expansion study of the HER2-directed antibody–drug conjugate T-Bren (BL-M07D1) in advanced breast cancer and other solid tumours

2026 · Herui Yao, Ruihua Zhao, et al. · EBioMedicine

Works count: 6

Citation count: 65

H-index: 2

I10-index: 2